Sands Capital Ventures
Latest statistics and disclosures from Sands Capital Alternatives's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NU, KVYO, BBNX, CPNG, DASH, and represent 73.02% of Sands Capital Alternatives's stock portfolio.
- Added to shares of these 2 stocks: IOT (+$6.0M), FIG.
- Started 1 new stock position in FIG.
- Reduced shares in these 2 stocks: DASH (-$79M), CPNG.
- Sands Capital Alternatives was a net seller of stock by $-74M.
- Sands Capital Alternatives has $456M in assets under management (AUM), dropping by -10.12%.
- Central Index Key (CIK): 0001846444
Tip: Access up to 7 years of quarterly data
Positions held by Sands Capital Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sands Capital Alternatives
Sands Capital Alternatives holds 20 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nu Hldgs Ord Shs Cl A (NU) | 25.2 | $115M | 7.2M | 16.01 |
|
|
| Klaviyo Com Ser A (KVYO) | 21.3 | $97M | 3.5M | 27.69 |
|
|
| Beta Bionics (BBNX) | 15.5 | $71M | 3.6M | 19.87 |
|
|
| Coupang Cl A (CPNG) | 5.6 | $26M | -6% | 795k | 32.20 |
|
| Doordash Cl A (DASH) | 5.4 | $25M | -76% | 90k | 271.99 |
|
| Samsara Com Cl A (IOT) | 4.9 | $22M | +36% | 599k | 37.25 |
|
| Inhibikase Therapeutics Com New (IKT) | 3.9 | $18M | 11M | 1.62 |
|
|
| Datadog Cl A Com (DDOG) | 3.7 | $17M | 119k | 142.40 |
|
|
| Monday SHS (MNDY) | 2.5 | $11M | 58k | 193.69 |
|
|
| Tarsus Pharmaceuticals (TARS) | 2.2 | $10M | 170k | 59.43 |
|
|
| Crowdstrike Hldgs Cl A (CRWD) | 1.7 | $7.7M | 16k | 490.38 |
|
|
| Snowflake Com Shs (SNOW) | 1.3 | $6.1M | 27k | 225.55 |
|
|
| Acumen Pharmaceuticals (ABOS) | 1.3 | $5.8M | 3.4M | 1.71 |
|
|
| Toast Cl A (TOST) | 1.3 | $5.7M | 157k | 36.51 |
|
|
| 10x Genomics Cl A Com (TXG) | 1.2 | $5.6M | 482k | 11.69 |
|
|
| Bioage Labs (BIOA) | 1.0 | $4.6M | 786k | 5.88 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.8 | $3.8M | 2.1M | 1.81 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.5 | $2.4M | 725k | 3.27 |
|
|
| Candel Therapeutics (CADL) | 0.5 | $2.1M | 406k | 5.10 |
|
|
| Figma Class A Com Stk (FIG) | 0.2 | $949k | NEW | 18k | 51.87 |
|
Past Filings by Sands Capital Alternatives
SEC 13F filings are viewable for Sands Capital Alternatives going back to 2021
- Sands Capital Alternatives 2025 Q3 filed Nov. 13, 2025
- Sands Capital Alternatives 2025 Q2 filed Aug. 13, 2025
- Sands Capital Ventures 2025 Q1 filed May 14, 2025
- Sands Capital Ventures 2024 Q4 filed Feb. 13, 2025
- Sands Capital Ventures 2024 Q3 filed Nov. 13, 2024
- Sands Capital Ventures 2024 Q1 filed May 14, 2024
- Sands Capital Ventures 2023 Q3 filed Nov. 14, 2023
- Sands Capital Ventures 2023 Q2 filed Aug. 15, 2023
- Sands Capital Ventures 2023 Q1 filed May 12, 2023
- Sands Capital Ventures 2022 Q4 filed Feb. 13, 2023
- Sands Capital Ventures 2022 Q3 filed Nov. 9, 2022
- Sands Capital Ventures 2022 Q2 filed Aug. 12, 2022
- Sands Capital Ventures 2022 Q1 filed May 13, 2022
- Sands Capital Ventures 2021 Q4 filed Jan. 21, 2022
- Sands Capital Ventures 2021 Q3 restated filed Nov. 12, 2021
- Sands Capital Ventures 2021 Q3 filed Nov. 4, 2021